TIDMAGY

RNS Number : 3040T

Allergy Therapeutics PLC

23 November 2021

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

Result of Annual General Meeting

23 November 2021 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that, with the exception of resolution 10, which failed to carry, all other resolutions proposed at the 2021 Annual General Meeting ("AGM") were duly passed by shareholders. Voting was conducted by way of a poll.

Resolutions 1 to 9 (inclusive) were proposed as ordinary resolutions and resolution 10 was proposed as a special resolution. The results of the poll are outlined in the table below.

The Board acknowledges the failure to pass resolution 10 and is disappointed in this outcome. The Board considers the flexibility afforded by these authorities to be in the best interests of the Company and shareholders and notes that this resolution has received support at previous AGMs. However, the Board remains committed to continuing an open and transparent dialogue and will, accordingly, seek to continue to engage with shareholders regarding their views in this area.

 
 Resolution                  For:          %age    Against:      %age    Withheld 
 1. To receive 
  a copy of the 
  Annual Report 
  for the year 
  ended 30 June 
  2021                       176,577,712   99.99             0       0           0 
                            ------------  ------  ------------  ------  ---------- 
 2. To approve 
  the Directors' 
  Remuneration 
  Report                     174,524,577   98.86     1,989,308    1.13      63,827 
                            ------------  ------  ------------  ------  ---------- 
 3. To re-appoint 
  Mary Tavener 
  as a Director              176,161,541   99.98         7,089    0.01     409,082 
                            ------------  ------  ------------  ------  ---------- 
 4. To re-appoint 
  Scott Leinenweber 
  as a Director              173,381,457   98.41     2,787,173    1.58     409,082 
                            ------------  ------  ------------  ------  ---------- 
 5. To re-appoint 
  Tunde Otulana 
  as a Director              176,161,541   99.98         7,089    0.01     409,082 
                            ------------  ------  ------------  ------  ---------- 
 6. To re-appoint 
  Peter Jensen 
  as a Director              173,387,212   98.84     2,022,948    1.15   1,167,552 
                            ------------  ------  ------------  ------  ---------- 
 7. To appoint 
  BDO LLP as auditors 
  of the Company             176,142,079   99.97        32,806    0.02     402,827 
                            ------------  ------  ------------  ------  ---------- 
 8. To authorise 
  the Directors 
  to determine 
  the Auditors 
  remuneration               176,577,712   99.99             0       0           0 
                            ------------  ------  ------------  ------  ---------- 
 9. To authorise 
  the Directors 
  to allot unissued 
  share capital 
  up to a specified 
  amount (s551)              176,565,019   99.98        11,693    0.01       1,000 
                            ------------  ------  ------------  ------  ---------- 
 10 Special Resolution: 
  To disapply pre-emption 
  provisions of 
  s561(1) of the 
  CoAct 2006 up 
  to a specified 
  amount                      37,107,171   21.00   139,469,541   78.99       1,000 
                            ------------  ------  ------------  ------  ---------- 
 

- ENDS -

For further information, please contact:

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

allergytherapeutics@consilium-comms.com

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines, that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGFEEFEDEFSEIF

(END) Dow Jones Newswires

November 23, 2021 07:54 ET (12:54 GMT)

Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Allergy Therapeutics Charts.
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Allergy Therapeutics Charts.